These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Marketing authorization for pharmaceuticals: the necessity of European collaboration]. Seitz R; Enzmann H Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):703-4. PubMed ID: 18592336 [No Abstract] [Full Text] [Related]
4. Can China bring its own pipeline to the market? Louët S Nat Biotechnol; 2004 Dec; 22(12):1497-9. PubMed ID: 15583646 [No Abstract] [Full Text] [Related]
5. [EU law on marketing authorization of medicines. History, current state of development and perspectives]. Nettesheim M Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):705-12. PubMed ID: 18560781 [TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical marketing in a new age. Effective campaigns still need to focus on what customers want. Rao SK Mark Health Serv; 2002; 22(1):6-12. PubMed ID: 11881547 [TBL] [Abstract][Full Text] [Related]
8. Good pharma, bad pharma. Drug Ther Bull; 2013 Aug; 51(8):85. PubMed ID: 23927857 [No Abstract] [Full Text] [Related]
9. Biotech drug market steadily expands. Lawrence S Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279 [No Abstract] [Full Text] [Related]
10. Pharmaceutical industry guide. Strange bedfellows? Moore A Health Serv J; 2002 Nov; 112(5833):suppl 13-5. PubMed ID: 12478712 [No Abstract] [Full Text] [Related]
11. New agreement on branded drugs for the NHS. Naci H; Dixon J BMJ; 2019 Jan; 364():l266. PubMed ID: 30658964 [No Abstract] [Full Text] [Related]
12. Getting new drugs to market: how individuals could do this without leaving their desks. Collier J BMJ; 2006 Dec; 333(7582):1315-7. PubMed ID: 17185722 [No Abstract] [Full Text] [Related]
13. [Marketing of medicinal products in the European Community. The Mutual Recognition and Decentralised Procedures]. Bachmann P Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):722-30. PubMed ID: 18560780 [TBL] [Abstract][Full Text] [Related]
15. An audience with...Sir John Sulston. Sulston J Nat Rev Drug Discov; 2005 Feb; 4(2):98. PubMed ID: 15756755 [No Abstract] [Full Text] [Related]
16. Sir Michael Rawlins on being NICE--and fair--about drug development and availability. Interview by Daniel Clarke. Rawlins SM Drug Discov Today; 2005 Mar; 10(6):383-6. PubMed ID: 15808816 [No Abstract] [Full Text] [Related]
17. What can Johnson & Johnson do to remain a giant in the health care industry? Carter T J Hosp Mark Public Relations; 2002; 14(1):93-103. PubMed ID: 12569997 [TBL] [Abstract][Full Text] [Related]
18. Surviving the blockbuster syndrome. Service RF Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490 [No Abstract] [Full Text] [Related]
19. New image for the drug industry. Cohen D BMJ; 2011 Nov; 343():d7713. PubMed ID: 22127772 [No Abstract] [Full Text] [Related]
20. Pharmaceutical industry guide. It all ads up. Moore A Health Serv J; 2002 Nov; 112(5833):suppl 17. PubMed ID: 12478713 [No Abstract] [Full Text] [Related] [Next] [New Search]